OC treatment increases caspase-3/7 activity, cleaving downstream targets such as PARP, a DNA repair enzyme, to execute programmed cell death, as observed in hepatocellular carcinoma (HCC) and CRC cells. This evidence concerns the gene PARP1 and hepatocellular carcinoma.